- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06424977
Stimolazione mirata ai biomarcatori per eventi epilettiformi (BTSEE)
Sicurezza ed efficacia della stimolazione mirata ai biomarcatori nell'epilessia
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: David Himes, BSEE
- Numero di telefono: 425-679-9505
- Email: dhimes@cadenceneuro.com
Luoghi di studio
-
-
California
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Lucile Packard Children's Hospital Stanford
-
Contatto:
- Swetapadma Patnaik
- Numero di telefono: (650) 721-1458
- Email: sweta@stanford.edu
-
Investigatore principale:
- Ann Hyslop Segeren, MD
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic
-
Contatto:
- Karla Crockett
- Numero di telefono: 507-538-9140
- Email: Crockett.Karla@mayo.edu
-
Investigatore principale:
- Nicholas Gregg, MD
-
-
Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Children's Medical Center
-
Contatto:
- Mariana Gallardo
- Numero di telefono: 682-303-4916
- Email: Mariana.Gallardo@cookchildrens.org
-
Investigatore principale:
- M. Scott Perry, MD
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Investigatore principale:
- Hannah Goldstein, MD
-
Contatto:
- Deborah Grenard
- Numero di telefono: 206-987-8078
- Email: Cadence@seattlechildrens.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subject is greater than or equal to 7 years of age.
- Subject has focal onset seizures.
- Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
- Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
- Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
- For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
- Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
- A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
- Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
- Subject has had a brain MRI epilepsy evaluation within the past two years.
- Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.
Exclusion Criteria:
-
Subject has a history of substance abuse within the preceding two years.
-
Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
-
Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
-
Subject has anatomy that may interfere with electrode placement.
-
Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
-
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
-
Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
-
Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
-
Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
-
Subject has primary generalized seizures.
-
Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
- The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
- Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
-
Subject, in the opinion of the Investigator, would be a poor study candidate.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Trattamento
|
Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adverse event rate
Lasso di tempo: Intervals through 7, 12, and 24 months post-implant
|
Determine adverse event rate, including adverse device effects and serious adverse events |
Intervals through 7, 12, and 24 months post-implant
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Seizure frequency
Lasso di tempo: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline. |
Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
|
Neurocognitive testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Depression testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Anxiety testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Quality of life testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Sleep testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Seizure severity testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Caregiver burden testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Suicidality risk testing
Lasso di tempo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25.
- Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20.
- Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6.
- Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283.
- Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CAD2004
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .